NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by Ludwig Institute for Cancer Research
Sponsor:
Collaborator:
Cancer Research Institute
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT01810016
First received: March 8, 2013
Last updated: January 16, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)